Added 1 month ago Drug news
AMAG Pharmaceuticals announced topline results from PROLONG, a randomized, double-blinded, placebo-controlled clinical trial evaluating Makena (progestin) in patients with a...
Added 11 months ago Drug news
Qiagen announced the U.S. regulatory approval of PartoSure, which is a novel test for assessing the risk of spontaneous preterm...
Added 3 years ago Drug news
FDA approves aingle dose formulation of Makena (hydroxyprogesterone caproate injection) for preterm labour -AMAG Pharmaceuticals
The FDA has approved a single-dose, preservative-free formulation of Makena (hydroxyprogesterone caproate injection) from AMAG Pharmaceuticals. Makena is the only...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.
This guideline covers the care of women at increased risk of or with symptoms and signs of preterm labour (before 37 weeks) and women having a planned preterm birth.
Added 3 years ago
Objective: The aim of the present study was to understand the role played by Atosiban, an oxytocin receptor antagonist, on...
Added 4 years ago